» Articles » PMID: 26573278

High-resolution Copy Number Analysis of Paired Normal-tumor Samples from Diffuse Large B Cell Lymphoma

Abstract

Copy number analysis can be useful for assessing prognosis in diffuse large B cell lymphoma (DLBCL). We analyzed copy number data from tumor samples of 60 patients diagnosed with DLBCL de novo and their matched normal samples. We detected 63 recurrent copy number alterations (CNAs), including 33 gains, 30 losses, and nine recurrent acquired copy number neutral loss of heterozygosity (CNN-LOH). Interestingly, 20 % of cases acquired CNN-LOH of 6p21 locus, which involves the HLA region. In normal cells, there were no CNAs but we observed CNN-LOH involving some key lymphoma regions such as 6p21 and 9p24.1 (5 %) and 17p13.1 (2.5 %) in DLBCL patients. Furthermore, a model with some specific CNA was able to predict the subtype of DLBCL, 1p36.32 and 10q23.31 losses being restricted to germinal center B cell-like (GCB) DLBCL. In contrast, 8p23.3 losses and 11q24.3 gains were strongly associated with the non-GCB subtype. A poor prognosis was associated with biallelic inactivation of TP53 or 18p11.32 losses, while prognosis was better in cases carrying 11q24.3 gains. In summary, CNA abnormalities identify specific DLBCL groups, and we describe CNN-LOH in germline cells from DLBCL patients that are associated with genes that probably play a key role in DLBCL development.

Citing Articles

Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.

Ho C, Gopal A, Till B, Shadman M, Lynch R, Cowan A Clin Lymphoma Myeloma Leuk. 2023; 24(2):e33-e39.e1.

PMID: 37926672 PMC: 10841534. DOI: 10.1016/j.clml.2023.10.002.


Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.

Magnes T, Wagner S, Thorner A, Neureiter D, Klieser E, Rinnerthaler G Cancers (Basel). 2021; 13(4).

PMID: 33561953 PMC: 7914762. DOI: 10.3390/cancers13040650.


A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.

Palmer A, Chidley C, Sorger P Elife. 2019; 8.

PMID: 31742555 PMC: 6897534. DOI: 10.7554/eLife.50036.


Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression.

Montes P, Bernal M, Campo L, Gonzalez-Ramirez A, Jimenez P, Garrido P Cancer Immunol Immunother. 2019; 68(12):2015-2027.

PMID: 31705171 PMC: 11028123. DOI: 10.1007/s00262-019-02420-x.


Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.

Gonzalez-Rincon J, Mendez M, Gomez S, Garcia J, Martin P, Bellas C PLoS One. 2019; 14(2):e0212813.

PMID: 30802265 PMC: 6388933. DOI: 10.1371/journal.pone.0212813.